AstraZeneca says efzimfotase alfa beats placebo on bone health endpoint in Phase III MULBERRY trial for pediatric hypophosphatasia

• AstraZeneca reported late-breaking Phase III MULBERRY results already presented at a children’s bone health meeting for efzimfotase alfa in pediatric hypophosphatasia.
• The study showed meaningful improvement in bone health versus placebo, with supportive signals in physical function and quality of life.
• Across the Phase III program, efzimfotase alfa showed a favorable tolerability profile, including fewer injection-site reactions versus historical Strensiq studies.
• In the Phase III CHESTNUT switch trial, safety was broadly similar to Strensiq, with bone-health measures maintained following the switch.
• Full Phase III HICKORY results in adolescents and adults will be presented at a future medical meeting, keeping a key readout pending.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AstraZeneca plc published the original content used to generate this news brief on June 28, 2026, and is solely responsible for the information contained therein.